Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Chemo-Immunotherapy combo beat standard care for tough lung cancer?

NCT ID NCT05856695

Ongoing Disease control Sponsor: Intergroupe Francophone de Cancerologie Thoracique Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This phase 2 trial is testing whether a chemotherapy combination without etoposide (carboplatin plus paclitaxel) plus the immunotherapy drug durvalumab works better than standard treatment for people with extensive-stage small cell lung cancer. About 67 participants will receive the drugs to see if it improves overall survival. The goal is to find a more effective first-line option for this aggressive cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Carboplatin, paclitaxel, and durvalumab (a type of immunotherapy)
What this could lead to
If successful, this could point toward a more effective first-line treatment for extensive-stage small cell lung cancer, potentially improving survival.
What could go wrong
This is a small, early-phase (phase 2) proof-of-concept study with only 67 participants. The combination may not prove superior to standard therapy, and side effects from chemotherapy and immunotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER EXTENSIVE STAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL LUNG CANCER EXTENSIVE STAGE

Contacts and locations

Locations

  • Abbeville - CH

    Abbeville, France

  • Amiens - Clinique de l'Europe

    Amiens, France

  • Angers - CHU

    Angers, France

  • Annemasse - CH

    Contamine-sur-Arve, France

  • Besançon - CHU

    Besançon, France

  • Bordeaux - CHU

    Bordeaux, France

  • Boulogne - Ambroise Paré

    Boulogne-Billancourt, France

  • CHU Montpellier

    Montpellier, 34295, France

  • CHU Toulouse

    Toulouse, 31059, France

  • Caen - CHU Côte de Nacre

    Caen, 14000, France

  • Chambéry - CH

    Chambéry, France

  • Cholet - CH

    Cholet, France

  • Colmar - CH

    Colmar, France

  • Créteil - CHI

    Créteil, France

  • Dijon - CHU Bocage

    Dijon, France

  • Grenoble - CHU

    Grenoble, France

  • Le Mans - CHG

    Le Mans, France

  • Lyon - URCOT

    Lyon, France

  • Marseille - APHM

    Marseille, France

  • Marseille - Hôpital Européen

    Marseille, France

  • Morlaix - CH

    Morlaix, France

  • Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg

    Strasbourg, 67091, France

  • Orléans - CHR

    Orléans, France

  • Paris - Bichat

    Paris, France

  • Paris - Hôpital Cochin

    Paris, France

  • Paris - Tenon

    Paris, France

  • Rennes - CHU

    Rennes, France

  • Toulon - Sainte Anne HIA

    Toulon, France

  • Tours - CHU

    Tours, France

  • Vandoeuvre-lès-Nancy - CRLCC

    Vandœuvre-lès-Nancy, France

  • Villefranche sur Saône - CH

    Villefranche-sur-Saône, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.